文献速递心力衰竭与心肌病

SGLT2抑制剂在糖尿病与心衰中降低高尿酸血症与痛风风险

Hyperuricemia and Gout Reduction by SGLT2 Inhibitors in Diabetes and Heart Failure: JACC Review Topic of the Week.
PubMed 文献 · J Am Coll Cardiol · 2024-01-01

本文综述SGLT2抑制剂在糖尿病和心衰患者中降低血尿酸及痛风风险的机制与证据。通过诱导「饥饿模拟」状态,SGLT2抑制剂减少嘌呤合成并促进尿酸排泄,大型临床试验显示其可降低血尿酸约0.6至1.5 mg/dL,痛风风险降低30%至50%。

要点

  • SGLT2抑制剂通过减少磷酸戊糖途径通量和促进尿酸排泄降低血尿酸。
  • 大型临床试验中血尿酸降低约0.6至1.5 mg/dL,痛风风险降低30%至50%。
  • 高尿酸血症是细胞应激的标志物而非驱动因素。

核心结论

  • SGLT2抑制剂通过诱导饥饿模拟状态减少嘌呤合成并促进尿酸排泄,从而降低血尿酸和痛风风险。

研究设计与样本

  • 本文为JACC综述,汇总SGLT2抑制剂在糖尿病和心衰中降低高尿酸血症与痛风的机制及临床试验证据。

主要发现

  • SGLT2抑制剂降低血尿酸约0.6至1.5 mg/dL。
  • 大型临床试验中SGLT2抑制剂使痛风风险降低30%至50%。

临床怎么用

  • 在糖尿病和心衰患者中使用SGLT2抑制剂时,可预期其降低血尿酸和痛风风险的额外获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gout is characterized by increased production of purines (through the pentose phosphate pathway), which is coupled with reduced renal or intestinal excretion of urate. Concurrent upregulation of nutrient surplus signaling (mammalian target of rapamycin and hypoxia-inducible factor-1a) and downregulation of nutrient deprivation signaling (sirtuin-1 and adenosine monophosphate-activated protein kinase) redirects glucose toward anabolic pathways (rather than adenosine triphosphate production), thus promoting heightened oxidative stress and cardiomyocyte and proximal tubular dysfunction, leading to cardiomyopathy and kidney disease. Hyperuricemia is a marker (rather than a driver) of these cellular stresses. By inducing a state of starvation mimicry in a state of nutrient surplus, sodium-glucose cotransporter-2 inhibitors decrease flux through the pentose phosphate pathway (thereby attenuating purine and urate synthesis) while promoting renal urate excretion. These convergent actions exert a meaningful effect to lower serum uric acid by ≈0.6 to 1.5 mg/dL and to reduce the risk of gout by 30% to 50% in large-scale clinical trials.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Packer. Hyperuricemia and Gout Reduction by SGLT2 Inhibitors in Diabetes and Heart Failure: JACC Review Topic of the Week. J Am Coll Cardiol. 2024. PMID: 38199714. doi:10.1016/j.jacc.2023.10.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。